Bellerophon Therapeutics Stock Price and Value Analysis

Should you buy Bellerophon Therapeutics stock? (NasdaqGM:BLPH). Let's see how it does in our automated value investing analysis system.

BLPH Free Cash Flow Trend

Free Cash Flow trendline for BLPH
Free Cash Flow trendline for Bellerophon Therapeutics

Hmm, we can't give any reliable projection for Bellerophon Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This stock looks overpriced.
  • This company is less known than others.
  • This company is not making money.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the BLPH Numbers

BLPH Price
(Bellerophon Therapeutics stock price per share)
[?] PE Ratio versus Sector 62% lower than other Healthcare stocks
[?] PE Ratio versus Industry 86% lower than other Biotechnology stocks
[?] Free Cash Flow Jitter 38%

Is Bellerophon Therapeutics Stock on Sale?

Based on our analysis, we believe that you should not buy Bellerophon Therapeutics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy BLPH Stock?

Does Bellerophon Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.